SCHEMBL2229185

SCHEMBL2229185

Cc1cc(C)nc(N2CCCN(c3ccc(NC(=O)C(=O)c4c(-c5ccccc5)cc5cccc(C)n45)cc3)CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.39
LMNA P02545 6/20 0.39
ALDH1A1 P00352 4/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 3/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC2A1 P11166 2/20 0.37
USP2 O75604 2/20 0.37
CNR1 P21554 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 2/20 0.37
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647640 0.98 MAPT (0.40) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL2231973 0.89 MAPT (0.41) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1645208 0.88 MAPT (0.51) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1989247 0.88 MAPT (0.40) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL2230930 0.86 ALDH1A1 (0.40) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1646439 0.86 MAPT (0.42) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1645045 0.86 MAPT (0.43) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1648138 0.85 MAPT (0.53) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL1127284 0.85 MAPT (0.42) MAPTLMNAALDH1A1HTTMEN1
SCHEMBL30234731 0.85 MAPT (0.42) MAPTLMNAALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885LMNA 3870/4885ALDH1A1 2813/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885LMNA 1805/4885ALDH1A1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.